

L4 ANSWER 7 OF 16 MEDLINE

DUPLICATE 5

AB In the present investigation, effect of rat peripheral polymorphonuclear leukocyte (PMNL) supernatant was investigated on **platelet aggregation**. Rat PMNLs suspended in Hanks balanced salt solution (HBSS, pH 7.4) were incubated at 37 degrees C for different time intervals

and cell-free supernatant was obtained by centrifugation. Supernatant was found to inhibit adenosine diphosphate (ADP), arachidonic acid (AA), and calcium ionophore-induced **platelet aggregation**. The inhibitory effect of PMNL supernatant on **platelet aggregation** was not blocked by methylene blue (10 microm) or adenosine deaminase (5 U ml(-1)) pretreatment, suggesting that the inhibitory effect of the supernatant on aggregation was not mediated by nitric oxide (NO) or **ecto-ADPase**. The effect of PMNL supernatant on **platelet aggregation** was abolished by preheating the supernatant at 95 degrees C for 5 minutes. Pretreatment of the supernatant with protease inhibitors abolished the inhibitory effect of supernatant on **platelet aggregation** suggesting that the factor may be a protein or peptide with protease activity. Partial purification of biologically active factor by fine particle liquid chromatography (FPLC) by using Superose 6B column yielded a peak with a molecular weight of approximately 30 kDa having antiaggregatory activity. The results obtained suggest that rat peripheral PMNLs release yet

another

factor(s) that inhibits **platelet aggregation**. The factor is a heat labile protein with a molecular weight of approximately 30 kDa.

AN 1998387478

MEDLINE

DN 98387478

TI Inhibition of **platelet aggregation** by a protein factor present in rat peripheral polymorphonuclear leukocyte supernatant.

AU Kumari R; Singh M P; Seth P; Dikshit M

CS Division of Pharmacology, Central Drug Research Institute, Lucknow, India.

SO THROMBOSIS RESEARCH, (1998 Jul 15) 91 (2) 75-82.

Journal code: VRN. ISSN: 0049-3848.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199901

File

L4 ANSWER 12 OF 16 MEDLINE

DUPLICATE 8

AB Platelet activation by the stable endoperoxide analogue U46619 is mediated

largely by ADP released from platelet-dense granules. Polymorphonuclear leukocytes (PMNs) endowed with **ecto-ADPase** activity may operate as antiaggregatory cells in **platelet aggregation** induced by U46619. Unstimulated PMNs were effective in reducing aggregation when platelets were stimulated by threshold concentrations of U46619, whereas at higher concentrations of the stimulus, PMN activation is required. Evidence that the inhibition was mediated by PMN **ecto-ADPase** activity was obtained by high-performance liquid chromatography analysis, indicating that PMNs were able to efficiently metabolize platelet-active ADP into AMP. Moreover, PMN-derived supernatants were able to inhibit **platelet aggregation**, suggesting that under this circumstance the inhibition was exerted by an uncharacterized, releasable ADPase activity. This study supports the hypothesis that, besides nitric oxide and hydrogen peroxide, ADPase activity may represent another PMN-mediated pathway capable of regulating platelet activity in areas of reduced blood flow, such as those found in conditions of myocardial ischemia.

=> d 14 12 bib

L4 ANSWER 12 OF 16 MEDLINE

DUPLICATE 8

AN 93250000 MEDLINE

DN 93250000

TI **Platelet aggregation** induced by the endoperoxide analogue U46619 is inhibited by polymorphonuclear leukocyte ADPase activity.

AU Zatta A; Pandolfo L; Caparrotta L; Prosdocimi M; Dejana E; Del Maschio A  
CS Fidia Research Laboratories, Abano Terme, Italy..

SO ARTERIOSCLEROSIS AND THROMBOSIS, (1993 May) 13 (5) 696-701.  
Journal code: AZ1. ISSN: 1049-8834.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199308

L4 ANSWER 14 OF 16 MEDLINE

DUPLICATE 9

AB We previously reported that platelets become unresponsive to agonists when

stimulated in combined suspension with aspirin-treated human umbilical vein endothelial cells. Inhibition occurred concomitant with metabolism

of platelet-derived endoperoxides to prostacyclin by endothelial cells. We now demonstrate that if aspirin-treated platelets which fully respond to appropriate doses of agonists are exposed to aspirin-treated endothelial cells, they remain unresponsive despite absence of prostacyclin. Platelet inhibition is due in large part to **ecto-ADPase** activity on the endothelial cells. This was established by incubating aspirin-treated endothelial cells with <sup>14</sup>C-ADP. Radio-thin layer chromatography and aggregometry demonstrated that <sup>14</sup>C-ADP and induction

of platelet activation decreased rapidly and concurrently. AMP accumulated transiently, was further metabolized to adenosine, and deaminated to inosine. The apparent K<sub>m</sub> of the endothelial cell ADPase was 33-42 microm and the V<sub>max</sub> 17-43 nmol/min per 10(6) cells, values in the range of antithrombotic potential. Thus, at least three complementary systems in human endothelial cells control platelet responsiveness: a cell-associated, aspirin-insensitive ADPase which functions in parallel with fluid phase autacoids such as the aspirin-inhibitable eicosanoids, and the aspirin-insensitive endothelium-derived relaxing factor.

=> d 14 14 bib

L4 ANSWER 14 OF 16 MEDLINE

DUPLICATE 9

AN 92042759 MEDLINE

DN 92042759

TI Inhibition of platelet function by an aspirin-insensitive endothelial cell

ADPase. Thromboregulation by endothelial cells.

AU Marcus A J; Safier L B; Hajjar K A; Ullman H L; Islam N; Broekman M J; Eiroa A M

CS Department of Medicine, Department of Veterans Affairs Medical Center, New York, NY 10010..

NC HL-18828-16 (NHLBI)

HL-47073-01 (NHLBI)

HL-46403 (NHLBI)

+

SO JOURNAL OF CLINICAL INVESTIGATION, (1991 Nov) 88 (5) 1690-6.

Journal code: HS7. ISSN: 0021-9738.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199202

(360) 546-2497  
503 292 7428

AB ~~CD39~~, or vascular adenosine triphosphate diphosphohydrolase, has been considered an important inhibitor of platelet activation. Unexpectedly, ~~cd39~~-deficient mice had prolonged bleeding times with minimally perturbed coagulation parameters. Platelet interactions with injured mesenteric vasculature were considerably reduced in vivo and purified mutant platelets failed to aggregate to standard agonists in vitro. This platelet hypofunction was reversible and associated with purinergic type P2Y1 receptor desensitization. In keeping with deficient vascular protective mechanisms, fibrin deposition was found at multiple organ sites in ~~cd39~~-deficient mice and in transplanted cardiac grafts. Our data indicate a dual role for adenosine triphosphate diphosphohydrolase in modulating hemostasis and thrombotic reactions.

AN 1999401080 MEDLINE  
DN 99401080  
TI Targeted disruption of ~~cd39~~/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation [see comments].  
CM Comment in: Nat Med 1999 Sep;5(9):987-8  
AU Enjyoji K; Sevigny J; Lin Y; Frenette P S; Christie P D; Esch J S 2nd; Imai M; Edelberg J M; Rayburn H; Lech M; Beeler D L; Csizmadia E; Wagner D; Robson S C; Rosenberg R D  
CS Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.  
NC HL57307 (NHLBI)  
PO1-41484 (NHLBI)  
HL41002  
SO NATURE MEDICINE, (1999 Sep) 5 (9) 1010-7.  
Journal code: CG5. ISSN: 1078-8956.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199912  
EW 19991201

Get

RB 11/3/03 37

transgenic  
post filing

L4 ANSWER 6 OF 16 MEDLINE DUPLICATE 4  
 AB Human placental ecto-ATP diphosphohydrolase (ATPDase), an 82 kDa single-chain glycoprotein, was purified to high specific activity using a specific murine monoclonal antibody MK33 (IgG1-kappa). Structurally, protein-based analysis showed this enzyme to be almost identical to that of **CD39** lymphoid cell activation antigen deduced by cDNA sequencing (Maliszewski CR, et al, J Immunol 1994; 153:3574); but differing in the NH2-terminal amino acid sequence, suggesting that placental ecto-ATPDase is most likely an isoform of CD39 generated by alternative splicing of the pre-mRNA. Functionally, placental ecto-ATPDase totally inhibits the secondary **platelet aggregation** induced by agonists at a final concentration (f.c.) of 1 microgram/ml. The purified enzyme (1 microgram/ml, final), pre-incubated with washed platelets prior to alpha-thrombin stimulation, completely inhibits the activation of platelet glycoprotein (GP) IIb/IIIa, thereby blocking the binding of fibrinogen or von Willebrand factor to platelets. Further, under different shear stresses, the enzyme modulates **platelet aggregation** differently. Low shear stress-induced **platelet aggregation** is blocked by this enzyme in a dose-dependent manner and is totally blocked at f.c. 0.5 microgram/ml. Under high shear stress, however, this protein at a f.c. of 0.5 microgram/ml mediates almost complete disaggregation of platelets without affecting the initial aggregation. Using immunohistochemical analysis, this enzyme was observed to be localized at the syncytiotrophoblasts of placental microvilli and the endothelial cells (ECs) of the umbilical vein obtained at full-term normal delivery, but scarcely at the ECs of the umbilical artery.

=> d 14 6 bib

L4 ANSWER 6 OF 16 MEDLINE DUPLICATE 4  
 AN 1999062444 MEDLINE  
 DN 99062444  
 TI Placental ecto-ATP diphosphohydrolase: its structural feature distinct from **CD39**, localization and inhibition on shear-induced **platelet aggregation**.  
 AU Makita K; Shimoyama T; Sakurai Y; Yagi H; Matsumoto M; Narita N; Sakamoto Y; Saito S; Ikeda Y; Suzuki M; Titani K; Fujimura Y  
 CS Department of the 2nd Internal Medicine of Nara Medical University, Japan.  
 SO INTERNATIONAL JOURNAL OF HEMATOLOGY, (1998 Oct) 68 (3) 297-310.  
 Journal code: A7F. ISSN: 0925-5710.  
 CY Ireland  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 EM 199903  
 EW 19990301

in mouse  
model?  
or den

L4 ANSWER 2 OF 16 MEDLINE DUPLICATE 1  
 AB The human ecto-apyrase gene family consists of five reported members (CD39, CD39-L1, CD39-L2, CD39-L3, and CD39-L4). The family can be subdivided into two groups by conservation of proposed structural domains. The CD39, CD39-L1, and CD39-L3 genes all encode hydrophobic portions in their carboxy and amino termini, serving as transmembrane domains for CD39 and potentially for the other two members. CD39-L2 and CD39-L4 genes encode hydrophobic portions in their amino termini, suggesting that they might encode secreted apyrases. We demonstrate that the CD39-L4 gene encodes the first reported human secreted ecto-apyrase. COS-7 cells transfected with a CD39-L4 expression construct utilizing the naturally occurring leader peptide express recombinant protein outside of the cells. This expression can be blocked by brefeldin A, a chemical that inhibits a step in mammalian secretory pathways. We also demonstrate expression of CD39-L4 message in macrophages, suggesting that the protein is present in the circulation. Furthermore, we show that CD39-L4 is an E-type apyrase, is dependent on calcium and magnesium cations, and has high degree of specificity for NDPs over NTPs as enzymatic substrates. A potential physiological role in hemostasis and **platelet aggregation** is presented.

=> d 14 2 bib

L4 ANSWER 2 OF 16 MEDLINE DUPLICATE 1  
 AN 1999329001 MEDLINE  
 DN 99329001  
 TI CD39-L4 is a secreted human apyrase, specific for the hydrolysis of nucleoside diphosphates.  
 AU Mulero J J; Yeung G; Nelken S T; Ford J E  
 CS Functional Genomics Department, Hyseq Inc., Sunnyvale, California 94086, USA.  
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 Jul 16) 274 (29) 20064-7.  
 Journal code: HIV. ISSN: 0021-9258.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals; Cancer Journals  
 EM 199910  
 EW 19991003

*fragment*  
*102a*

L4 ANSWER 11 OF 16 MEDLINE  
 AN 97115858 MEDLINE  
 DN 97115858  
 TI Identification and characterization of **CD39**/vascular ATP  
 diphosphohydrolase.  
 AU Kaczmarek E; Koziak K; Sevigny J; Siegel J B; Anrather J; Beaudoin A R;  
 Bach F H; Robson S C  
 CS Sandoz Center for Immunobiology, New England Deaconess Hospital, Harvard  
 Medical School, Boston, Massachusetts 02215, USA..  
 srobson@nedhmail.nedh.harvard.edu  
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1996 Dec 20) 271 (51) 33116-22.  
 Journal code: HIV. ISSN: 0021-9258.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals; Cancer Journals  
 OS GENBANK-U87967  
 EM 199703

DUPLICATE 7

=> d 14 11 ab

L4 ANSWER 11 OF 16 MEDLINE  
 AB Vascular ATP diphosphohydrolase (ATPDase) is a plasma membrane-bound  
 enzyme that hydrolyses extracellular ATP and ADP to AMP. Analysis of  
 amino  
 acid sequences available from various mammalian and avian ATPDases  
 revealed their close homology with **CD39**, a putative B-cell  
 activation marker. We, therefore, isolated **CD39** cDNA from human  
 endothelial cells and expressed this in COS-7 cells. **CD39** was  
 found to have both immunological identity to, and functional  
 characteristics of, the vascular ATPDase. We also demonstrated that  
 ATPDase could inhibit **platelet aggregation** in response  
 to ADP, collagen, and thrombin, and that this activity in transfected  
 COS-7 cells was lost following exposure to oxidative stress. ATPDase mRNA  
 was present in human placenta, lung, skeletal muscle, kidney, and heart  
 and was not detected in brain. Multiple RNA bands were detected with the  
**CD39** cDNA probe that most probably represent different splicing  
 products. Finally, we identified an unique conserved motif, DLGGASTQ,  
 that  
 could be crucial for nucleotide binding, activity, and/or structure of  
 ATPDase. Because ATPDase activity is lost with endothelial cell  
 activation, overexpression of the functional enzyme, or a truncated  
 mutant  
 thereof, may prevent platelet activation associated with vascular  
 inflammation.

Get

AB The glycoprotein (GP) IIb/IIIa (the  $\alpha$ IIb  $\beta$ 3 integrin) found on platelets binds fibrinogen or von Willebrand factor when the platelet is activated, thereby mediating the aggregation of platelets. Blockade of the

GPIIb/IIIa should prevent **platelet aggregation** independent of the substance or substances responsible for activating the platelets. This comprehensive inhibition of **platelet aggregation** is thought to be an effective therapeutic approach to various clinical thromboembolic syndromes. This study investigated the platelet inhibition provided by blocking GPIIb/IIIa by using a new nonpeptidic molecule, BIBU52, in both in vitro and in vivo models. BIBU52 competes with [ $^{125}$ I]fibrinogen for binding sites on human platelets in a  $\text{Ca}^{2+}$  and pH-dependent manner with a 50% inhibitory concentration ( $\text{IC}_{50}$ )

of 35  $\pm$  12 nM. BIBU52 inhibited the aggregation of human platelets in platelet-rich plasma induced by collagen (1-2  $\mu\text{g}/\text{ml}$ ), adenosine diphosphate (ADP; 2.5  $\mu\text{M}$ ), and a thrombin receptor-activating peptide (TRAP; SFLLRNPNDKYEPF-NH $_2$ ; 25  $\mu\text{M}$ ) with  $\text{IC}_{50}$  values of 82, 83, and 200 nM, respectively. The inhibition of **platelet aggregation** by BIBU52 was found to be highly species dependent. BIBU52 inhibited aggregation in plasma from rhesus and marmoset monkeys with an  $\text{IC}_{50}$  of 150 nM but was totally ineffective in

rat plasma. The selectivity of BIBU52 for inhibiting GPIIb/IIIa in comparison with other adhesion molecules was investigated in a human endothelial

cell adhesion assay. The adhesion of human endothelial cells to matrices of vitronectin, fibronectin, collagen I, or laminin was not affected by concentrations as high as 100  $\mu\text{M}$  BIBU52; thus BIBU52 demonstrates a high selectivity for the human GPIIb/IIIa. The antithrombotic effect of BIBU52 in vivo was investigated in three **animal models** of recurrent arterial thrombus formation. In the guinea pig aorta, BIBU52 inhibited thrombus formation dose dependently, with lack of thrombus formation for 1 h after a bolus dose of 1.0 mg/kg i.v.. Both acetylsalicylic acid and dazoxiben were less effective in this model. In pigs with recurrent thrombus formation in the carotid artery, 1.0 mg/kg i.v. also inhibited thrombus formation. Heparin was not effective in the pig, and acetylsalicylic acid was only partially effective. In the pig, the dose of 1.0 mg/kg i.v. BIBU52 also was associated with a 70% inhibition of collagen-induced **platelet aggregation** ex vivo but with only a transient prolongation of sublingual bleeding time

to a maximum of 2.5-fold and without other hemodynamic effects. In the marmoset monkey, a dose of 10  $\mu\text{g}/\text{kg}$  i.v. could abolish recurrent arterial **thrombosis**. Hemodynamic effects of BIBU52 in anesthetized pigs were not detected in doses  $\leq$  10 mg/kg. These data demonstrate that BIBU52 is a potent and selective antagonist of the human GPIIb/IIIa receptor and capable of substantial inhibition of **platelet aggregation** in vitro and ex vivo as well as inhibition of arterial thrombus formation in vivo in **animal models of thrombosis**.

=> d 17 9 bib



AN 97413541 MEDLINE  
DN 97413541  
TI Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule  
BIBU52: inhibition of **platelet aggregation** in vitro  
and antithrombotic efficacy in vivo.  
AU Guth B D; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Muller T H  
CS Department of Biological Research, Dr. Karl Thomae GmbH, Biberach an der  
Riss, Germany.  
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, (1997 Aug) 30 (2) 261-72.  
Journal code: K78. ISSN: 0160-2446.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199712  
EW 19971201

RM345.J68